The phrase "favourable benefit" is not correct and is generally considered redundant in written English.
You can use it when discussing advantages or positive outcomes, but it is better to choose one term.
Example: "The new policy provides a favourable benefit to all employees, improving their work-life balance."
Alternatives: "advantageous benefit" or "positive benefit."
By 1938 the area planted yearly was, with the favourable benefit of reducing erosion in the Cotter catchment.
The case control studies show more favourable benefit of screening compared with the trials.
Three studies showed the superiority of low molecular weight heparins in terms of a favourable benefit risk ratio in this indication [ 22- 24] in comparison to oral anticoagulants.
Despite a favourable benefit package, share of total health expenditure in GDP is minimum, increased from 3.3% of GDP in 2001 to 4.0% in 2008.
On the whole, the favourable benefit:risk ratio for early corticoid therapy would advocate the prescription of dexamethasone at the beginning of treatment of purulent meningitis in children when it is probably due to the usual community bacteria.
The 5-year ATLAS data confirm that the early clinical improvements and safety profile seen with adalimumab in patients with AS are maintained through 5 years of treatment, supporting a favourable benefit:risk profile for the long-term use of adalimumab in patients with AS.
Her claim that Britain had a far more favourable benefits regime was immediately challenged by Downing St, who said they were addressing such "pull factors".
FUTURE-1 study and past studies suggest a favourable benefit-risk profile for bosentan at 2 mg/kg b.i.d., this dose is recommended for children with PAH.
However, according to the G-BA, the therapeutic benefit required for a drug to be reimbursable by the German sick funds is not identical to the therapeutic efficacy and the favourable benefit-risk ratio proven by the marketing authorisation [11].
Given the favourable benefit-to-risk ratio, parathyroidectomy should be performed as early as possible and, in case of late diagnosis, even during the third trimester [ 1- 3].
Overall, the results from the GO-MORE study suggest that adding golimumab to several different non-biological DMARD has a favourable benefit-to-risk profile in a broader RA patient population than was studied in previous clinical trials.
